Wave Life Sciences Q4 net income $29.3M; cash $302M; obesity and AATD data expected in 2025

Wave Life Sciences Ltd.

Q4 2024 revenue $83.7M (up from $29.1M YoY); net income $29.3M vs prior year net loss $16.3M.
Full year 2024 net loss $97.0M, compared to $57.5M in 2023; R&D expenses increased to $159.7M.
Cash $302.1M as of Dec 31, 2024, expected operating runway into 2027; excludes potential GSK milestones.
Dosing underway in INLIGHT trial of WVE-007 in obesity; clinical data expected 2H 2025.
On track to deliver FORWARD-53 48-week DMD data and FDA feedback on accelerated approval in 1Q 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.